The UK government has selected Pfizer over GSK to supply millions of doses of its Abrysvo RSV vaccine for older adults and pregnant mothers, dealing a blow to the British pharmaceutical giant. Pfizer's contract includes over 3.5 million doses for older adults and more than 1.4 million for pregnant mothers, with deliveries set to begin in July. While GSK's Arexvy vaccine had shown significant success in the US, Pfizer's competitive pricing and broader approval for pregnant women likely contributed to its selection. The decision represents a setback for GSK in its efforts to dominate the RSV vaccine market, despite its previous successes and confidence in its product's value and efficacy.